摘要
目的:了解武汉地区医院口服抗糖尿病药的利用情况与发展趋势。方法:对武汉地区24家医院2006～2008年口服抗糖尿病药的应用品种、销售金额、用药频度(DDDs)及日均费用(DDC)等进行统计、分析。结果:该地区医院口服抗糖尿病药的销售金额和DDDs逐年增加,DDC呈下降趋势。在销售金额及DDDs排序中靠前的包括二甲双胍、阿卡波糖、瑞格列奈等,三者3年销售金额之和所占比例达60.06%,DDDs之和占41.65%,其中二甲双胍的DDC最低,2008年为3.48元/日。结论:武汉地区医院口服抗糖尿病药用药结构较为合理、稳定。α葡萄糖苷酶抑制剂和双胍类制剂在当前及今后的糖尿病治疗中占主导地位,阿卡波糖和二甲双胍为最受临床认可的品种。
OBJECTIVE：To investigate the utilization and tendency of oral antidiabetic drugs in Wuhan area. METHODS：The utilization of oral antidiabetic drugs in 24 hospitals of Wuhan area during the period of 2006～2008 were analyzed statistically in respect of category of drugs,consumption sum,DDDs and DDC. RESULTS：The consumption sum and DDDs of oral antidiabetic drugs increased year by year while the DDC descended. Top 3 oral antidiabetic drugs in the list of consumption sum and DDDs were dimethyl biguanide,acarbose and repaglinide. The consumption sum of them in 3 years occupied 60.06%,DDDs occupied 41.65%. DDC of dimethyl biguanide was lowest among 3 kinds of drugs,3.48 yuan per day in 2008. CONCLUSION：The utiliza- tion of oral antidiabetic drugs in Wuhan area is rational and stable gradually. α-glucosidase enzyme inhibitors and biguanides take up the lead place of the therapy of diabete. Acarbose and dimethyl biguanide are popular in the clinic.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第42期3954-3958,共5页
China Pharmacy
